A patent review of apelin receptor (APJR) modulators (2014-2019)

References

• Folino A, Montarolo PG, Samaja M, et al. Effects of apelin on the cardiovascular system. Heart Fail Rev. 2015;20:505–518.
   PubMed Web of Science ®Google Scholar
• Dalzell JR, Rocchiccioli JP, Weir RA, et al. The emerging potential of the apelin-APJ system in heart failure. J Card Fail. 2015;21:489–498.
   PubMed Web of Science ®Google Scholar
• Bertrand C, Valet R, Castan-Laurell I. Apelin and energy metabolism. Front Physiol. 2015;6:115.
   PubMed Web of Science ®Google Scholar
• O’Dowd BF, Heiber M, Chan A, et al. A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene. 1993;136:355–360.
   PubMed Web of Science ®Google Scholar
• Tatemoto K, Hosoya M, Habata Y, et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun. 1998;251:471–476.
   PubMed Web of Science ®Google Scholar
• Maguire JJ, Kleinz MJ, Pitkin SL, et al. [Pyr1]apelin-13 identified as the predominant apelin isoform in the human heart. Hypertension. 2009;54:598–604.
   PubMed Web of Science ®Google Scholar
• Zhen EY, Higgs RE, Gutierrez JA. Pyroglutamyl apelin-13 identified as the major apelin isoform in human plasma. Anal Biochem. 2013;442:1–9.
   PubMed Web of Science ®Google Scholar
• Cano Martinez LJ, Coral Vazquez RM, Mendez JP, et al. Serum concentration of apelin-17 isoform vary in accordance to blood pressure categories in individuals with obesity class 3. Clin Exp Hypertens. 2018;41:168–173.
   Web of Science ®Google Scholar
• Chng SC, Ho L, Tian J, et al. Elabela: a hormone essential for heart development signals via the apelin receptor. Dev Cell. 2013;27:672–680.
   PubMed Web of Science ®Google Scholar
• Pauli A, Norris ML, Valen E, et al. Toddler: an embryotic signal that promotes cell movement via apelin receptors. Science. 2014;343:1248636.
   PubMed Web of Science ®Google Scholar
• Yang PR, Maguire JJ, Davenport AP. Elabela/Toddler,and biased agonists as novel therapeutic agents in the cardiovascular system. Trends Pharmacol Sci. 2015;36:560–567.
   PubMed Web of Science ®Google Scholar
• Cai X, Bai B, Zhang R, et al. Apelin receptor homodimer-oligomers revealed by single-molecule imaging and novel G protein-dependent signaling. Sci Rep. 2017;7:40335.
   PubMed Web of Science ®Google Scholar
• Zou MX, Liu HY, Haraguchi Y, et al. Apelin peptides block the entry of human immunodeficiency virus (HIV). FEBS Lett. 2000;473:15–18.
   PubMed Web of Science ®Google Scholar
• Japp AG, Cruden NL, Barnes G, et al. Acute cardiovascular effects of apelin in humans: potential role in patients with chronic heart failure. Circulation. 2010;121:1818–1827.
   PubMed Web of Science ®Google Scholar
• Xi Y, Yu D, Yang R, et al. Recombinant Fc-Elabela fusion protein has extended plasma half-life and mitigates post-infarct heart dysfunction in rats. Int J Cardiol. 2019;292:180–187.
   PubMed Web of Science ®Google Scholar
• Vickers C, Hales P, Kaushik V, et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem. 2002;277:14838−43.
   PubMed Web of Science ®Google Scholar
• Wang W, McKinnie SM, Farhan M, et al. Angiotensin converting enzyme 2 metabolizes and partially inactivates pyr-apelin-13 and apelin-17: physiological effects in the cardiovascular system. Hypertension. 2016;68:365−77.
   PubMed Web of Science ®Google Scholar
• McKinnie SMK, Fischer C, Tran KMH, et al. The metalloprotease neprilysin degrades and inactivates apelin peptides. ChemBioChem. 2016;17:1495−8.
   PubMed Web of Science ®Google Scholar
• Fischer C, Lamer T, Wang W, et al. Plasma kallikrein cleaves and inactivates apelin17: Palmitoyl and PEG-extended apelin 17 analogs as metabolically stable blood pressure-lowering agents. Eur J Med Chem. 2019;166:119–124.
   PubMed Web of Science ®Google Scholar
• Huang A, He L, Chen Z, et al. Targeting drugs to APJ receptor: from signaling to pathophysiological effects. J Cell Physiol. 2019;234:61–74.
   Web of Science ®Google Scholar
• Mughal A, O’Rourke ST. Vascular effects of apelin: mechanisms and therapeutic potential. Pharmacol Ther. 2018;190:139–147.
   PubMed Web of Science ®Google Scholar
• Narayanan S, Harris DL, Maitra R, et al. Regulation of the apelinergic system and its potential in cardiovascular disease: peptides and small molecules as tools for discovery. J Med Chem. 2015;58:7913–7927.
   PubMed Web of Science ®Google Scholar
• Read C, Nyimanu D, Williams TL, et al. International union of basic and clinical pharmacology. CVII. Structure and pharmacology of the apelin receptor with a recommendation that elabela/toddler is a second endogenous peptide ligand. Pharmacol Rev. 2019;71:467–502.
   PubMed Web of Science ®Google Scholar
• Raymer B, Ebner D. Small molecule and peptide therapeutics for chronic heart failure: a patent review (2011–2014). Expert Opin Ther Patents. 2015;25:1175–1190.
   PubMed Web of Science ®Google Scholar
• Vaidya B, Pangallo M, Ruffenach G, et al. Advances in treatment of pulmonary arterial hypertension: a patent review. Expert Opin Ther Patents. 2017;27:907–918.
   PubMed Web of Science ®Google Scholar
• Iturrioz X, Alvear-Perez R, De Mota N, et al. Identification and pharmacological properties of E339-3D6, the first nonpeptidic apelin receptor agonist. Faseb J. 2010;24:1506–1517.
   PubMed Web of Science ®Google Scholar
• Khan P, Maloney PR, Hedrick M, et al. Functional agonists of the apelin (APJ) receptor. Probe reports from the NIH Molecular Libraries Program. 2011. Bethesda, MD: National Center for Biotechnology Information.
   Google Scholar
• Lagorce D, Sperandio O, Baell JB, et al. FAF-Drug3: a web server for compound property calculation and chemical library design. Nucleic Acids Res. 2015;43:W200–W207.
   PubMed Web of Science ®Google Scholar
• Sanofi. Benzoimidazole-carboxylic acid amide derivatives as APJ receptor modulators. WO2014044738. 2014.
   Google Scholar
• Read C, Fitzpatrick CM, Yang P, et al. Cardiac action of the first G protein biased small molecule apelin agonist. Biochem Pharmacol. 2016;116:63–72.
   PubMed Web of Science ®Google Scholar
• Read C, Fitzpatrick CM, Yang P, et al. CMF-019, the first G protein biased small molecule apelin agonist, is a vasodilator and positive inotrope in vivo (Abtract), in APSA-ASCEPT 2017 joint scientific meeting 2017. Brisbane, Australia: APSA-ASCEPT. 2017:33.
   Google Scholar
• Sanford-Burnham Medical Research Institute. Apelin receptor agonists and methods of use thereof. WP2016176473. 2016.
   Google Scholar
• Bristol-Myers Squibb company. 2-[1,1ʹ-Biphenyl]-1H-1benzo[D]imidazole derivatives and related compounds as apelin and APJ agonists for treating cardiovascular diseases. WO2019036024. 2019.
   Google Scholar
• Trifonov L, Afri M, Palczewski K, et al. An expedient synthesis of CMF-019: (S)-5-methyl-3-{1-(pentan-3-yl)-2-(thiophen-2-ylmethyl)-1H-benzo[d]imidazole-5-carboxamido}hexanoic acid, a potent apelin receptor (APJ) agonist. Med Chem. 2018;14:688–694.
   PubMed Web of Science ®Google Scholar
• Su S, Clarke A, Han Y, et al. Biphenyl acid derivatives as APJ receptor agonists. J Med Chem. 2019;62:10456–10465.
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb company. 4-Hydroxy-3-[heteroaryl]pyridine-2-one APJ agonists for the use in the treatment of cardiovascular disorders. WO2016196771. 2016.
   Google Scholar
• Bristol-Myers Squibb company. 2,4-Dihydroxy-nicotinamides as APJ agonists. WO2017066402. 2017.
   Google Scholar
• Bristol-Myers Squibb company. 4-Hydroxy-3-sulfonylpyridin-2[1H]-ones as APJ receptor agonists. WO2017218617. 2017.
   Google Scholar
• Bristol-Myers Squibb company. 3-Sulfonyl-5-aminopyridine-2,4-diol APJ agonists. WO2018071622. 2018.
   Google Scholar
• Bristol-Myers Squibb company. 6-Hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as APJ agonists. WO2017165640. 2017.
   Google Scholar
• Bristol-Myers Squibb company. 6-Hydroxy-5-[phenyl/heteroarylsulfonyl]pyrimidin-4[1H]-one as APJ agonists. WO2017218633. 2017.
   Google Scholar
• Bristol-Myers Squibb company. Heteroarylhydroxypyrimidinones as agonists of the APJ receptor. WO2017106396. 2017.
   Google Scholar
• Bristol-Myers Squibb company. Apelin receptor agonists and methods of use. WO2017096130. 2017.
   Google Scholar
• Amgen Inc. Substituted pyrimidinones as agonists of the APJ receptor. WO2019213006. 2019.
   Google Scholar
• Research Triangle Institute. Apelin receptor [APJ] agonists and uses thereof. WO2015188073. 2015.
   Google Scholar
• Narayanan S, Maitra R, Deschamps JR, et al. Discovery of a novel small molecule agonist scaffold for the APJ receptor. Bioorg Med Chem. 2016;24:3758–3770.
   PubMed Web of Science ®Google Scholar
• Sanford-Burnham Medical Research Institute. Agonists of the apelin receptor and methods of use thereof. WO2015184011. 2015.
   Google Scholar
• Sanford-Burnham Prebys Medical Discovery Institute. Novel azole derivatives as apelin receptor agonists. WO2017091513. 2017.
   Google Scholar
• Amgen Inc. Heterocyclic triazole compounds as agonists of the APJ receptor. WO2017192485. 2017.
   Google Scholar
• Amgen Inc. Heteroaryl-substituted triazoles as APJ receptor agonists. WO2018097945. 2018.
   Google Scholar
• Amgen Inc. Triazole phenyl compounds as agonists of the APJ receptor. WO2018093579. 2018.
   Google Scholar
• Amgen Inc. Triazole furan compounds as agonists of the APJ receptor. WO2018097944. 2018.
   Google Scholar
• Amgen Inc. Triazole pyridyl compounds as agonists of the APJ receptor. WO2018093580. 2018.
   Google Scholar
• Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the APJ receptor. WO2018093577. 2018.
   Google Scholar
• Amgen Inc. Alkyl substituted triazole compounds as agonists if the APJ receptor. WO2018093576. 2018.
   Google Scholar
• Amgen Inc. Fused triazole agonists of the APJ receptor. WO2019089335. 2019.
   Google Scholar
• Research Triangle Institute. Imposed apelin receptor (APJ) agonists and uses thereof. WO2017100558. 2017.
   Google Scholar
• Research Triangle Institute. Heterocyclic apelin receptor [APJ] agonists and uses thereof. WO2018071526. 2018.
   Google Scholar
• Annapurna Bio Inc. Compounds and compositions for treating conditions associated with APJ receptor activity. WO2019169193. 2019.
   Google Scholar
• Goetze JP, Rehfeld JF, Carlsen J, et al. Apelin: a new plasma marker of cardiovascular disease. Regul Pept. 2006;133:134–138.
   PubMed Web of Science ®Google Scholar
• Chandra SM, Razavi H, Kim J, et al. Disruption of the apelin-APJ system worsens hypoxia-induced pulmonary hypertension. Arterioscler Thromb Vasc Biol. 2011;31:814–820.
   PubMed Web of Science ®Google Scholar
• Wang W, Shen M, Fischer C, et al. Apelin protects against abdominal aortic aneurysm and the therapeutic role of neutral endopeptidase resistant apelin analogs. Proc Natl Acad Sci USA. 2019;116:13006–13015.
   PubMed Web of Science ®Google Scholar
• Yang P, Read C, Kuc RE, et al. Elabela/toddler is an endogeneous agonist of the apelin APJ receptor in the adult cardiovascular system, and exogeneous administration of the peptide compensates for the downregulation of its expression in pulmonary arterial hypertension. Circulation. 2017;135:1160–1173.
   PubMed Web of Science ®Google Scholar
• Li Y, Yang X, Ouyang S, et al. Declined circulating elabela levels in patients with essential hypertension and its association with impaired vascular function: a preliminary study. Clin Exp Hypertens. 2019;22:1–5.
   Google Scholar
• Novartis AG Synthetic linear apelin mimetics for the treatment of heart failure. WO2014081702. 2014.
   Google Scholar
• Murza A, Tran K, Bruneau-Cossette L, et al. Apelins, elabela, and their derivatives: peptidic regulators of the cardiovascular system and beyond. Pept Sci. 2019;111:e24064.
   Web of Science ®Google Scholar
• McKinnie SMK, Wang W, Fischer C, et al. Synthetic modification within the ‘RPRL’ region of apelin peptides: impact on cardiovascular activity and stability to neprilysin and plasma degradation. J Med Chem. 2017;60:6408–6427.
   PubMed Web of Science ®Google Scholar
• Genzyme Corporation. Pegylated apelin and uses thereof. WO2012125408. 2012.
   Google Scholar
• Jia ZQ, Hou L, Leger A, et al. Cardiovascular effects of a pegylated apelin. Peptides. 2012;133:147–154.
   Google Scholar
• The Governors of the University of Alberta. Apelin peptides and uses thereof. WO2019008438. 2019.
   Google Scholar
• Oefner C, D’Arcy A, Hennig M, et al. Structure of human neutral endopeptidase (neprilysin) complexed with phosphoramidon. J Mol Biol. 2000;296:341–349.
   PubMed Web of Science ®Google Scholar
• Masoud AGT, Lin JX, Farhan MA, et al. Apelin directs endothelial cell differentiation and vascular repair following immune-mediated injury. J Clin Invest. 2020;130:94–107.
   PubMed Web of Science ®Google Scholar
• University of Ulster. Apelin analogues. WO2015165936. 2015.
   Google Scholar
• O’Harte FPM, Parthsarathy V, Hogg C, et al. Acetylated apelin-13 amide analogue exhibits enzyme resistance and prolonged insulin releasing, glucose lowering and anorexic properties. Biochem Pharmacol. 2017;146:165–173.
   PubMed Web of Science ®Google Scholar
• O’Harte FPM, Parthsarathy V, Hogg C, et al. Long-term treatment with acetylated analogues of apelin-13 amide ameliorates diabetes and improves lipid profile of high-fat fed mice. PLoS ONE. 2018;13:e0202350.
   PubMed Web of Science ®Google Scholar
• INSERM. Metabolically stable apelin analogs in the treatment of disease mediated by the apelin receptor. WO2016102648. 2016.
   Google Scholar
• Université de Strasbourg, INSERM, La Recherche Médicale, Centre National de la Recherche Scientifique, Collége de France. Metabolically stable peptide analogs. WO2017216359. 2017.
   Google Scholar
• Gerbier R, Alvear-Perez R, Margathe JF, et al. Development of original metabolically stable apelin-17 analogs with diuretic and cardiovascular effects. Faseb J. 2017;31:687–700.
   PubMed Web of Science ®Google Scholar
• Juhl C, Els-Heindl S, Schönauer R, et al. Development of potent and metabolically stable APJ ligands with high therapeutic potential. ChemMedChem. 2016;11:2378–2384.
   PubMed Web of Science ®Google Scholar
• Amgen Inc. Apelin polypeptides. WO2015191781. 2015.
   Google Scholar
• Amgen Inc. APJ receptor agonists and uses thereof. WO2014099984. 2014.
   Google Scholar
• Hamada J, Kimura J, Ishida J, et al. Evaluation of novel cyclic analogues of apelin. Int J Mol Med. 2008;22:547–552.
   PubMed Web of Science ®Google Scholar
• Brame AL, Maguire JJ, Yang P, et al. Design, characterization and first-in-human study of the vascular actions of a novel biased apelin receptor agonist. Hypertension. 2015;65:834–840.
   PubMed Web of Science ®Google Scholar
• Lanthiopep BV. Cyclic apelin analogs. WO2015147641. 2015.
   Google Scholar
• Novartis AG. Cyclic apelin derivatives for the treatment of heart failure. WO2015013165. 2015.
   Google Scholar
• Novartis AG. Bioconjugates of synthetic apelin polypeptides. WO2015013169. 2015.
   Google Scholar
• Regeneron Pharmaceuticals, Inc. Apelin fusion proteins and uses thereof. WO2016116842. 2016.
   Google Scholar
• Regeneron Pharmaceuticals, Inc. Apelin fusion proteins and uses thereof. WO2016061141. 2016.
   Google Scholar
• Hirasawa S, Kitahara Y, Okamatsu Y, et al. Facile and efficient chemoenzymatic semisynthesis of Fc-fusion compounds for halt-life extension of pharmaceutical components. Bioconjugate Chem. 2019;30:2323–2331.
   PubMed Web of Science ®Google Scholar
• Regeneron Pharmaceuticals, Inc. Apelin fusion proteins and uses thereof. WO2014152955. 2014.
   Google Scholar
• Wang W, Zhang D, Yang R, et al. Hepatic and cardiac beneficial effects of a long-acting Fc-apelin fusion protein in diet-induced obese mice. Diabetes Metab Res Rev. 2018;34:e2997.
   PubMed Web of Science ®Google Scholar
• Extended Biosciences, Inc. Therapeutic Vitamine D conjugates. WO2016065042. 2016
   Google Scholar
• Koszowska AU, Nowak J, Dittfeld A, et al. Obesity, adipose tissue function and the role of vitamin D. Cent Eur J Immunol. 2014;39:260–264.
   PubMed Web of Science ®Google Scholar
• Faridvand Y, Bagherpour-Hassanlouei N, Nozari S, et al. 1, 25-Dihydroxyvitamin D3 activates Apelin/APJ system and inhibits the production of adhesion molecules and inflammatory mediators in LPS-activated RAW264.7 cells. Pharmacol Rep. 2019;71:811–817.
   Web of Science ®Google Scholar
• Anchor Therapeutics, Inc. APJ receptor compounds. WO2015010045. 2015.
   Google Scholar
• McKeown SC, Zecri FJ, Fortier E, et al. The design and implementation of a generic lipopeptide scanning platform to enable the identification of ‘locally acting’ agonists for the apelin receptor. Bioorg Med Chem Lett. 2014;24:4871–4875.
   PubMed Web of Science ®Google Scholar
• Sanford-Burnham Medial Research Institute. Small molecule antagonists of the apelin receptor for the treatment of disease. US20140005181. 2014.
   Google Scholar
• Maloney PR, Khan P, Hedrick M, et al. Discovery of 4-oxo-6-((pyrimidin-2-ylthio)methyl)-4H-pyran-3-yl-4-nitrobenzoate (ML221) as a functional antagonist of the apelin (APJ) receptor. Bioorg Med Chem Lett. 2012;22:6656–6660.
   PubMed Web of Science ®Google Scholar
• Ishimaru Y, Shibagaki F, Yamamuro A, et al. An apelin receptor antagonist prevents pathological retinal angiogenesis with ischemic retinopathy in mice. Sci Rep. 2017;7:15062.
   PubMed Web of Science ®Google Scholar
• Xiong Q, He W, Wang H, et al. Effect of the spinal apelinAPJ system on the pathogenesis of chronic constriction injury induced neuropathic pain in rats. Mol Med Rep. 2017;16:1223–1231.
   PubMed Web of Science ®Google Scholar
• Sanford Burnham Prebys Medical Discovery Institute. 4-Aminoquinoline compounds for the treatment of angiogenesis. WO2019173482. 2019.
   Google Scholar
• McAnally D, Siddiquee K, Gomaa A, et al. Repurposing antimalarial aminoquinolines and related compounds for treatment of retinal neovascularization. PLoS One. 2018;13:e202436.
   Web of Science ®Google Scholar
• Lee DK, Saldivia VR, Nguyen T, et al. Modification of the terminal residue of apelin-13 antagonizes its hypotensive action. Endocrinology. 2005;146:231–236.
   PubMed Web of Science ®Google Scholar
• Tiani C, Garcia-Pras E, Mejias M, et al. Apelin signaling modulates splanchnic angiogenesis and portosystemic collateral vessel formation in rats with portal hypertension. J Hepatol. 2009;50:296–305.
   PubMed Web of Science ®Google Scholar
• Yang P, Kuc RE, Brame AL, et al. [Pyr1]Apelin-13(1-12) is a biologically active ACE2 metabolite of the endogenous cardiovascular peptide [Pyr1]Apelin-13. Front Neurosci. 2017;11:92.
   PubMed Web of Science ®Google Scholar
• INSERM, Université Paris-Sud XI, Universite de Bordeaux. Polypeptides as apelin inhibitors and uses thereof. WO2013153049. 2013.
   Google Scholar
• Muto J, Shirabe K, Yoshizumi T, et al. The apelin-APJ system induces tumor arteriogenesis in hepatocellular carcinoma. Anticancer Res. 2014;34:5313–5320.
   PubMed Web of Science ®Google Scholar
• Davenport AP, Glen RC, Maguire JJ. Compounds for use as apelin receptor antagonists. WO2019193355. 2019.
   Google Scholar
• McAnally D, Siddiquee K, Sharir H, et al. A systematic approach to identify biased agonists of the apelin receptor through high-throughput screening. SLAS Discovery. 2017;22:867–878.
   PubMed Web of Science ®Google Scholar
• Zhou N, Fang J, Acheampong E, et al. Binding of alx40-4cto apj, a cns-based receptor inhibits its utilization as a co-receptor by hiv-1. Virology. 2003;312:196–203.
   PubMed Web of Science ®Google Scholar
• Doranz BJ, Filion LG, Diaz-Mitoma F, et al. Safe use of the cxcr4 inhibitor alx40-4c in humans. Aids Res Hum Retroviruses. 2001;17:475–486.
   PubMed Web of Science ®Google Scholar
• Macaluso NJM, Pitkin SL, Maguire JJ, et al. Discovery of a competitive apelin receptor (apj) antagonist. Chemmedchem. 2011;6:1017–1023.
   PubMed Web of Science ®Google Scholar
• Gonidec SL, Chaves-Almagro C, Bai Y, et al. Protamine is an antagonist of the apelin receptor, and its activity is reversed by heparin. Faseb J. 2018;31:2507–2519.
   Web of Science ®Google Scholar
• Butterworth J, Lin YA, Prielipp RC, et al. Rapid disappearance of protamine in adults undergoing cardiac operation with cardiopulmonary bypass. Ann Thorac Surg. 2002;74:15891595.
   PubMed Web of Science ®Google Scholar
• Amgen Inc., Lu SC, Wang M. Apelin antigen-binding proteins and uses thereof. WO2013012855. 2013.
   Google Scholar
• Regeneron Pharmaceuticals, Inc. APLNR modulators and uses thereof. WO2015077491. 2015.
   Google Scholar
• Gerbier R, Leroux C, Couvineau P, et al. New structural insights into the apelin receptor: identification of key residues for apelin binding. Faseb J. 2015;29:314–322.
   PubMed Web of Science ®Google Scholar
• IMBA GmbH. Combination of an apelin antagonist and an angiogenesis inhibitor for the treatment of cancer. WO2017174758. 2017.
   Google Scholar
• Kawamata Y, Habata Y, Fukusumi S, et al. Molecular properties of apelin: tissue distribution and receptor binding. Biochim Biophys Acta. 2001;1538:162–171.
   PubMed Web of Science ®Google Scholar
• Puffer BA, Sharron M, Coughlan CM, et al. Expression and Coreceptor function of APJ for primate immunodeficiency viruses. Virology. 2000;276:435–444.
   PubMed Web of Science ®Google Scholar
• Pinilla-Vera M, Hahn VS, Kass DA. Leveraging signaling pathways to treat heart failure with reduced ejection fraction. Circ Res. 2019;124:1618–1632.
   PubMed Web of Science ®Google Scholar
• Ma Y, Yue Y, Ma Y, et al. Structural basis for apelin control of the human apelin receptor. Structure. 2017;25:858–866.
   PubMed Web of Science ®Google Scholar
• Vardeny O, Tacheny T, Solomon SD. First-in-class angiotensin receptor neprilysin inhibitor in heart failure. Clin Pharmacol Ther. 2013;94:445–448. DOI: 10.1038/clpt.2013.146.
   PubMed Web of Science ®Google Scholar